Patients with OCTN2 high-expressing tumor had a significantly lower risk of recurrence (HR = 0.35, 95% CI 0.19–0.64) and death (HR = 0.37, 95% CI 0.14–0.96) (Table 2; Figure 4). The gene discussed is SLC22A5; the disease is neoplasm.